The Spanish Association of Biocompanies (AseBio) has highlighted how biotechnology is favoring the emergence of new therapeutic strategies that act differently from traditional antibiotics, with the aim of tackling multidrug-resistant bacteria.
Antimicrobial resistance has been consolidated as one of the major challenges for global public health. In Spain, the Ministry of Health estimates that around 4,000 people die each year from infections caused by resistant bacteria.
In this context, and on the occasion of World Awareness Week on Antimicrobial Resistance, which takes place from this Wednesday through next Tuesday, AseBio has wanted to make visible the work of two of its member companies, Telum Therapeutics and Microviable Therapeutics.
As the association has explained, Telum Therapeutics is driving a new generation of antimicrobials based on enzymes designed through protein engineering. Thanks to its technological platform "APEXp", it combines fragments of natural enzymes to generate new proteins with specific properties against particular bacteria.
Its main candidate, EPLETTX1, targets "Acinetobacter baumannii", a bacterium capable of causing serious infections, especially pneumonias in hospitalized patients. This treatment has obtained encouraging preclinical results in both laboratory studies and experimental infection models.
The company is now working to continue advancing its development and complete the regulatory studies required, with the goal of starting the first trials in humans at the beginning of 2028. "The real challenge is not only to discover a technology capable of destroying resistant bacteria, but to manage to turn it into a safe, effective and accessible medicine for those who need it," said Roberto Díez, founder of Telum Therapeutics.
Intestinal microbiota and new therapeutic options
Another research pathway that is opening up therapeutic alternatives focuses on using the intestinal microbiota to eradicate resistant bacteria and reduce the recurrence of infections.
On this line, microbiota transplantation from healthy donors has demonstrated its ability to eliminate the pathogen responsible for infections by "Clostridioides difficile" and its application against other resistant microorganisms, such as "Escherichia coli", "Klebsiella pneumoniae" and "Enterococcus", is being studied.
This has been detailed by Claudio Hidalgo, scientific cofounder and general director of Microviable Therapeutics. This biotechnology develops two experimental medicines in the form of oral capsules that contain live bacteria naturally present in the intestinal microbiota.
The first, MVT-201, is an ultrapurified product made from intestinal microbiota from healthy donors that has shown an efficacy greater than 98 percent in animal models to eliminate antibiotic multi-resistant bacteria and prevent the reappearance of infections. It is currently in the process of regulatory evaluation with the purpose of moving forward to clinical trials.
On the other hand, MVT-3501, in the preclinical phase, is a live biotherapeutic composed of a defined consortium of bacterial strains that act synergistically against resistant pathogens.
Hidalgo has underscored the major challenges involved in the manufacturing, stability, regulation and financing of this type of product and, in this sense, he has reiterated that research into antibiotic resistance "is an underfunded field, at the public and private level".